Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 37 results.
User Information
Export Records
  1. 1.   Complete Rescue of HTLV-1p12KO Infectivity by Depletion of Monocytes Together with NK and CD8+ T Cells
  2. Gutowska, Anna; Sarkis, Sarkis; Rahman, Mohammad Arif; Goldfarbmuren,Kate; Moles, Ramona; Bissa, Massimiliano; Doster, Melvin; Washington-Parks, Robyn; McKinnon, Katherine; Silva de Castro, Isabela; Schifanella, Luca; Franchini, Genoveffa; Pise-Masison, Cynthia A
  3. Pathogens (Basel, Switzerland). 2024, Mar 29; 13(4):
  1. 2.   Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia
  2. Winn, Blake A; Devkota, Laxman; Kuch, Bunnarack; MacDonough, Matthew T; Strecker, Tracy E; Wang, Yifan; Shi, Zhe; Gerberich, Jeni L; Mondal, Deboprosad; Ramirez, Alejandro J; Hamel,Ernest; Chaplin, David J; Davis, Peter; Mason, Ralph P; Trawick, Mary Lynn; Pinney, Kevin G
  3. Journal of natural products. 2020, APR 24; 83(4): 937-954.
  1. 3.   MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells
  2. Viola, G.; Bortolozzi, R.; Hamel, E.; Moro, S.; Brun, P.; Castagliuolo, I.; Ferlin, M. G.; Basso, G.
  3. Biochemical Pharmacology. 2012, Jan; 83(1): 16-26.
  1. 4.   Structure and function of RapA: A bacterial Swi2/Snf2 protein required for RNA polymerase recycling in transcription
  2. Jin, D. J.; Zhou, Y. N.; Shaw, G.; Ji, X. H.
  3. Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms. 2011, Sep; 1809(9): 470-475.
  1. 5.   mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
  2. Jiang, Q.; Weiss, J. M.; Back, T.; Chan, T.; Ortaldo, J. R.; Guichard, S.; Wiltrout, R. H.
  3. Cancer Research. 2011, Jun; 71(12): 4074-4084.
  1. 6.   Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies
  2. Gursel, D. B.; Connell-Albert, Y. S.; Tuskan, R. G.; Anastassiadis, T.; Walrath, J. C.; Hawes, J. J.; Amlin-Van Schaick, J. C.; Reilly, K. M.
  3. Neuro-Oncology. 2011, Jun; 13(6): 610-621.
  1. 7.   Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine
  2. Boltz, V. F.; Zheng, Y.; Lockman, S.; Hong, F. Y.; Halvas, E. K.; McIntyre, J.; Currier, J. S.; Chibowa, M. C.; Kanyama, C.; Nair, A.; Owino-Ong'or, W.; Hughes, M.; Coffin, J. M.; Mellors, J. W.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, May; 108(22): 9202-9207.
  1. 8.   Ethnoepidemiology of HTLV-1 related diseases: Ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal
  2. Sonoda, S.; Li, H. C. A.; Tajima, K.
  3. Cancer Science. 2011, Feb; 102(2): 295-301.
  1. 9.   Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production
  2. Zhang, S. L.; Readinger, J. A.; DuBois, W.; Janka-Junttila, M.; Robinson, R.; Pruitt, M.; Bliskovsky, V.; Wu, J. Z.; Sakakibara, K.; Patel, J.; Parent, C. A.; Tessarollo, L.; Schwartzberg, P. L.; Mock, B. A.
  3. Blood. 2011, Jan; 117(4): 1228-1238.
  1. 10.   Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits
  2. Valeri, V. W.; Hryniewicz, A.; Andresen, V.; Jones, K.; Fenizia, C.; Bialuk, I.; Chung, H. K.; Fukumoto, R.; Parks, R. W.; Ferrari, M. G.; Nicot, C.; Cecchinato, V.; Ruscetti, F.; Franchini, G.
  3. Blood. 2010, Nov; 116(19): 3809-3817.
  1. 11.   Interaction between the HTLV-I envelope and cellular proteins: impact on virus infection and restriction
  2. Ilinskaya, A.; Heidecker, G.; Jones, K.
  3. Future Medicinal Chemistry. 2010, Nov; 2(11): 1651-1668.
  1. 12.   Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission
  2. Van Prooyen, N.; Gold, H.; Andresen, V.; Schwartz, O.; Jones, K.; Ruscetti, F.; Lockett, S.; Gudla, P.; Venzon, D.; Franchini, G.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2010, Nov; 107(48): 20738-20743.
  1. 13.   The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity In vitro and In vivo
  2. Banerjee, S.; Byrd, J. N.; Gianino, S. M.; Harpstrite, S. E.; Rodriguez, F. J.; Tuskan, R. G.; Reilly, K. M.; Piwnica-Worms, D. R.; Gutmann, D. H.
  3. Cancer Research. 2010, Feb; 70(4): 1356-1366.
  1. 14.   Natural product scaffolds as leads-to drugs
  2. Newman, D. J.; Cragg, G. M.
  3. Future Medicinal Chemistry. 2009, Nov; 1(8): 1415-1427.
  1. 15.   The Receptor Complex Associated with Human T-Cell Lymphotropic Virus Type 3 (HTLV-3) Env-Mediated Binding and Entry Is Distinct from, but Overlaps with, the Receptor Complexes of HTLV-1 and HTLV-2
  2. Jones, K. S.; Huang, Y. K.; Chevalier, S. A.; Afonso, P. V.; Petrow-Sadowski, C.; Bertolette, D. C.; Gessain, A.; Ruscetti, F. W.; Mahieux, R.
  3. Journal of Virology. 2009 83(10): 5244-5255.
  1. 16.   Regulation and Function of Proline Oxidase Under Nutrient Stress
  2. Pandhare, J.; Donald, S. P.; Cooper, S. K.; Phang, J. M.
  3. Journal of Cellular Biochemistry. 2009 107(4): 759-768.
  1. 17.   Phenotypic and genotypic comparisons of human T-cell leukemia virus type I reverse transcriptases from infected T-cell lines and patient samples
  2. Mitchell, M. S.; Bodine, E. T.; Hill, S.; Princler, G.; Lloyd, P.; Mitsuya, H.; Matsuoka, M.; Derse, D.
  3. Journal of Virology. 2007, May; 81(9): 4422-4428.
  1. 18.   Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012
  2. Flys, T.; Nissley, D. V.; Claasen, C. W.; Jones, D.; Shi, C. J.; Guay, L. A.; Musoke, P.; Mmiro, F.; Strathern, J. N.; Jackson, J. B.; Eshleman, J. R.; Eshleman, S. H.
  3. Journal of Infectious Diseases. 2005, JUL 1; 192(1): 24-29.
  1. 19.   NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Hollingshead, M. G.
  3. Anticancer Research. 2005, MAY-JUN; 25(3B): 1865-1869.
  1. 20.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 21.   Prediagnostic human T lymphotropic virus type I provirus loads were highest in Jamaican children who developed seborrheic dermatitis and severe anemia
  2. Maloney, E. M.; Nagai, M.; Hisada, M.; Soldan, S. S.; Goebel, P. B.; Carrington, M.; Sawada, T.; Brennan, M. B.; Cranston, B.; Hanchard, B.; Jacobson, S.
  3. Journal of Infectious Diseases. 2004 189(1): 41-45.
  1. 22.   Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase
  2. Jankowsky, J. L.; Fadale, D. J.; Anderson, J.; Xu, G. M.; Gonzales, V.; Jenkins, N. A.; Copeland, N. G.; Lee, M. K.; Younkin, L. H.; Wagner, S. L.; Younkin, S. G.; Borchelt, D. R.
  3. Human Molecular Genetics. 2004 13(2): 159-170.
  1. 23.   Regulation of the cell-surface expression of an HTLV-1 binding protein in human T cells during immune activation
  2. Nath, M. D.; Ruscetti, F. W.; Petrow-Sadowski, C.; Jones, K. S.
  3. Blood. 2003 101(8): 3085-3092.
  1. 24.   A cohort study of health effects of human T-cell lymphotropic virus type I infection in Jamaican children
  2. Maloney, E. M.; Wiktor, S. Z.; Palmer, P.; Cranston, B.; Pate, E. J.; Cohn, S.; Kim, N.; Miley, W.; Thomas, T. L.; Blattner, W. A.; Hanchard, B.
  3. Pediatrics. 2003 112(2): E116-E122.
  1. 25.   Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice
  2. Papadopoulou, M. V.; Ji, M.; Ji, X. H.; Bloomer, W. D.; Hollingshead, M. G.
  3. Cancer Chemotherapy and Pharmacology. 2002 50(6): 501-508.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel